AnaptysBio director Laura Hamill resigns; Rita Jain appointed to board and compensation committee

ANAPTYSBIO, INC

Laura J. Hamill resigned as Class II director effective April 1, 2023; no disagreement with company.
Rita Jain, M.D. appointed as Class II director and Compensation Committee member effective April 3, 2023.
Jain receives pro-rata annual retainer: option for 8,015 shares at April 3 closing price, 3,234 RSUs vesting at 2024 annual meeting.
Additional grants: option for 10,600 shares and 3,900 RSUs, each vesting over three years.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Rita Jain

Class II director and member of Compensation Committee

ANAB · ANAPTYSBIO, INC

Effective: 2023-04-03
Filed: April 6, 2023, 7:59 PM ET

On April 3, 2023, the Board appointed Rita Jain, M.D. as a Class II director and as a member of the Compensation Committee, effective immediately.

Departed

Laura J. Hamill

Class II director

ANAB · ANAPTYSBIO, INC

Effective: 2023-04-01
Filed: April 6, 2023, 7:59 PM ET

On April 1, 2023, Laura J. Hamill advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that she would resign as a Class II director of the Board, effective on April 1, 2023 (the “ Resignation ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rita Jain was appointed as Class II director and member of Compensation Committee at ANAPTYSBIO, INC.

Action: appointed
Role: Class II director and member of Compensation Committee

Exact text from the filing

On April 3, 2023, the Board appointed Rita Jain, M.D. as a Class II director and as a member of the Compensation Committee, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Laura J. Hamill resigned as Class II director at ANAPTYSBIO, INC.

Action: resigned
Role: Class II director

Exact text from the filing

On April 1, 2023, Laura J. Hamill advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that she would resign as a Class II director of the Board, effective on April 1, 2023 (the “ Resignation ”).

View on SEC.gov

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-23-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.